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Submitted Jan 16, 2013; accepted May 7, 2013.DISCUSSIONDr Timur Sarac (Cleveland, Ohio). We presented our data at
the Cleveland Clinic approximately 5 years ago and found that our
reintervention rates in this cohort of patients was very high, and
you have taught us now a new way of doing this to really decrease
and cut down on the second procedure. I have two questions for
you.
One is could you please really give us the details of the tech-
nical aspects of using these stents, speciﬁcally in relation to do youﬂare the stent at all? And if so, what level can you take these
atriums to?
And then the second question I have is related to the SMA.
In some patients, we note that there is a long-segment stenosis
or even occlusion, which we have been more aggressive recently
in treating these. And do you use the iCAST in the SMA, or do
you go to a self-expanding stent where you’d go over that long
curve?
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we really reﬁned our technique, and there are several things that
need to be done to reduce restenosis rate.
I think one of the key points is to size the lesion and to make
sure that you use a stent that is of adequate size. We have learned
from looking at the restenosis that some of the patients were
undertreated and, in fact, either the lesion was missed distally or
proximally at the ostia.
So that brings us to the second point, which is ﬂaring of the
stent. I am really fond of ﬂaring out the stent for two reasons:
one is avoiding missing an ostial lesion and also facilitating recathe-
terization in the event that you need to do a reintervention. And I
tend to ﬂare it using the same balloon most of the time; or if I am
really concerned, upsizing the balloon by 1 or 2 mm.
In terms of some of the technical points of the iCAST, there
are certainly limitations with this. And I would say aside of the
fact that it is approximately three times more expensive, it does
require a larger introducer sheath, which becomes a problem for
those that are fond of using a brachial approach; it is subjected
to dislodgement from the balloon, which has signiﬁcantly
improved with newer technology. There is some risk of covering
side branches such as a large replaced hepatic artery. So, we still
do use uncovered stents on that bend of the SMA. A self-expand-
able stent also becomes a good and attractive option for lesions
beyond the ostia that involve tortuous segments. And, we have
cases that we use the hybrid stent with iCAST proximally for the
ostia and then a self-expandable uncovered stent for the proximal
to midportion of the SMA.
Dr Ali AbuRahma (Charleston, WVa). Gus, I really compli-
ment what you have done over the last several years in this ﬁeld,
and it has been an education to all of us.
The question that I have for you is: What duplex velocity
criteria did you use to validate these in-stent stenoses? And did
you validate these duplex velocities?
Dr Oderich. This is also a very important point and is the
main reason why there is such a variation between rates of resteno-
sis in different reports. The criteria that we use to deﬁne restenosis,
which I think is very debatable, is a peak systolic velocity of approx-
imately 330 cm/s for the SMA. This is based on several recent
reports including yours, Dr AbuRahma. We have not validated
a duplex ultrasound criteria at our institution for in-stent resteno-
sis. The main reason is that we found it difﬁcult to justify doing
angiography on a patient with “high velocities” who is asymptom-
atic and does not need reintervention.
I have to say, though, that there are many patients that despite
the high velocities, still have a widely patent stent. So the curves
that you see for primary patency in our study have included
patients with a restenosis associated with recurrent symptoms or
that require a reintervention, or an occlusion of the stent. Thesewere the criteria that we used; we have not used asymptomatic
restenosis diagnosed by ultrasound. For the purpose of the presen-
tation, I shied away from showing curves of freedom from resteno-
sis, which I think are highly debatable in how you deﬁne that given
that we do not obtain angiography in all patients.
Dr Amy Reed (Hershey, Pa). I just wanted to have you
comment on two things. First, for those BMS that failed, how
many of those did you wind up rescuing with the covered stent,
or did you have to go on to open revascularization?
And also could you comment, just a technical detail about the
management of antiplatelet therapy, if it was long term, if it was
different for the covered vs the uncovered?
Dr Oderich. I think if you have used a balloon-expandable
stent for the ﬁrst intervention, you have the luxury of being able
to size the second stent to the same size of the original stent. So
the answer is yes, for failed BMS, we offer a reintervention ideally
with a covered stent. Repeated restenosis is a different issue, and
the approach somewhat varies in our group, but my general
approach is still to offer to that patient that has a recurrence another
endovascular attempt. And I think the patients that we can predict
that are going to have repeated attempts are the long lesions in
the small vessels, female patients with dense calciﬁcations. And
most certainly in those patients, particularly if they are deemed
good surgical candidates, a bypass I think is a very good alternative.
Importantly, provided that you are careful and you do not compro-
mise the mid to distal portion of the SMAwith your initial endovas-
cular procedure, I do not think you burn any bridges. As for medical
therapy with CS, we recommend clopidogrel for the ﬁrst 6-8 weeks
followed by aspirin, which is the same as with a BMS. This is based
on the fenestrated endografts literature where clopidogrel is usually
not needed as a long-term therapy.
Dr Hasan Dosluoglu (Buffalo, NY). Great paper, and it
supports my bias, so thank you very much for that. I thought
you were going to say that you now routinely perform intravascular
ultrasound (IVUS), as you stated that you usually found the stents
to be undersized. So do you actually use IVUS during these proce-
dures, or do you not?
Dr Oderich. No. So I do not do IVUS for these cases, but I
do use CTA as our main preoperative workup test, and I tend to
size the length and the diameter using centerline or actual dimen-
sions to select the stent.
Dr John Ricotta (Washington, D.C.). This is a sequential
series, so presumably, the covered stents were done later in the
course of the series. Did you look at your BMS patency over
time to see whether it was an issue of technique getting better
that affected some of this?
Dr Oderich. The short answer is I have not, but I think this is
a very good methodological point that we should do for the
manuscript.
